Mindfulness-based Dance/Movement Therapy for Chronic Low Back Pain

Sponsor
Drexel University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03986489
Collaborator
National Center for Complementary and Integrative Health (NCCIH) (NIH), Stony Brook University (Other)
64
1
2
39
1.6

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the feasibility, acceptability and credibility of a mindfulness-based dance/movement therapy (M-DMT) protocol that is delivered online; to assess and improve methodological procedures for conducting a randomized controlled trial (RCT) test of M-DMT; and to demonstrate proof of principle by gathering information about the process of change between M-DMT and a control condition.

This is the first study to address the potential of M-DMT as a creative, non-opioid intervention for chronic back pain. Therefore, the findings of this study will provide important methodological and protocol data and substantive pilot data necessary for the next phase of this line of research, namely a fully powered RCT to evaluate efficacy and treatment mechanisms of action. Data obtained as part of this study will be instrumental for informing the systematic evaluation of M-DMT for chronic back pain care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness-based dance/movement therapy (M-DMT)
  • Behavioral: Chronic pain social support group
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
64 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Mindfulness-based Dance/Movement Therapy for Chronic Low Back Pain
Actual Study Start Date :
Apr 1, 2019
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness-based dance/movement therapy

Participants assigned to the M-DMT group condition will receive care as usual plus 12 weekly 90-minute group M-DMT sessions delivered online by a board-certified dance/movement therapist. The therapist is instructed to follow the M-DMT manualized protocol.

Behavioral: Mindfulness-based dance/movement therapy (M-DMT)
M-DMT includes benefits of physical activity, group psychotherapy, mindfulness training, and an art-based intervention in a unified practice. Each online session focuses on different psycho-educational topics about chronic low back pain management and links these topics with specific M-DMT activities that incorporate mindfulness-based principles and techniques.
Other Names:
  • Dance/Movement Therapy
  • Active Comparator: Chronic pain social support group

    Participants assigned to the control condition will participate in a 12-session (90-minute session/week) online social support group.

    Behavioral: Chronic pain social support group
    The therapist will facilitate online open group discussions about participants' experiences with or reactions to the topic of discussion and will promote empathy among group members. The therapist will use client-centered, reflective listening techniques but will not prescribe any specific recommendations for change. Each week, SSG participants will receive emails with brief information about the topic discussed during the group session.

    Outcome Measures

    Primary Outcome Measures

    1. Feasibility of Recruitment: Number of participants eligible [Baseline]

      Number of participants eligible for randomization to the study intervention

    2. Recruitment Rate [Baseline]

      Proportion of participants randomized relative to total trial referrals

    3. Recruitment time [Baseline]

      Number of participate enrolled per month

    4. Feasibility of recruiting male participants: Proportion of male participant enrolled [Baseline]

      Proportion of male participant enrolled to the study

    5. Treatment Completion Rate [12 weeks following receipt of treatment]

      We expect 80% of participants to complete at least 9/12 M-DMT sessions

    6. Retention Rate [24 weeks]

      Proportion of participants who complete follow-up questionnaires

    7. Reason for withdrawal [12 weeks following receipt of treatment]

      Assessed by an open-ended question, "What was the reason for discontinuing your participation?" administered by a study staff during a phone interview

    8. M-DMT intervention credibility and expectancy [1 week]

      Credibility/Expectancy Questionnaire (range 3-27; higher scores reflect greater treatment expectancy and rationale credibility)

    9. Treatment Fidelity [1-12 weeks]

      Treatment fidelity assessment form developed by the researcher (range: varies between sessions depending on the number of items included in the particular session; A total score of 80% and higher reflects adequate treatment fidelity)

    10. Treatment satisfaction and acceptability: Likert-scale survey [12 weeks post-randomization]

      via Likert-scale surveys; on scale of 1 to 5, 1 being not satisfied; 5 being very satisfied (i.e higher number, better outcome).

    11. M-DMT intervention acceptability [12 weeks]

      Exit interview based on an interview protocol developed by the researcher

    12. Adverse Event [1 -12 weeks]

      Number of adverse events

    Secondary Outcome Measures

    1. Pain intensity: PROMIS® Pain Intensity-Short Form (SF)3a [Change from Baseline pain intensity at 6, 12, and 24-week time points]

      PROMIS® Pain Intensity-Short Form (SF)3a (A 5-point (from 1= Had no pain to 5= Very Severe) rating scale is used in each of the 3 items; higher results mean higher intensity of pain.

    2. Pain interference: PROMIS® Pain Interference -8a [Change from Baseline pain interference at 6, 12, and 24-week time points]

      PROMIS® Pain Interference -8a (A 5-point (from 1= Not at all to 5= Very much) rating scale is used on each of the 8 items; higher scores reflect greater pain interference

    3. Chronic pain acceptance: Chronic Pain Acceptance Questionnaire [Change from Baseline chronic pain acceptance at 6, 12, and 24-week time points]

      Chronic Pain Acceptance Questionnaire (A seven-point (from 0= Never to 6 = Always) rating scale is used in each of the 20 items; higher results mean high pain acceptance)

    4. Mindfulness [Change from Baseline mindfulness at 6, 12, and 24-week time points]

      Cognitive and Affective Mindfulness Scale (A 4-point (Rarely/not at all to almost always) rating scale is used in each of the 12 items; higher values reflect higher mindful qualities

    5. Physical activity (Accelerometry data) [Change from Baseline physical activity at 12, and 24-week time points]

      An accelerometer, ActiGraph GT9X will be used to measure the change in participants physical activity between baseline and 2 endpoints (12 and 24 weeks)

    6. Physical activity (Self-report data) [Change from Baseline physical activity at 6, 12, and 24-week time points]

      Self-report assessment of physical activity will be done through UCLA Activity Scale (One item out of 10 will be checked to best describe current activity level)

    Other Outcome Measures

    1. Physical Function [Change from Baseline physical function at 6, 12, and 24-week time points]

      PROMIS® Physical function-20a (A 5-point (5= without any difficulty to 1= Unable to do) rating scale is used in each of the 20 items; higher values reflect higher abilities to physically function

    2. Depression [Change from Baseline depression at 6, 12, and 24-week time points]

      PROMIS® Emotional Distress-Depression-SF 4a (A 5-point (1= Never to 5= Always) rating scale is used in each of the 4 items; higher values reflect higher levels of depression

    3. Sleep Disturbance [Change from Baseline sleep disturbance at 6, 12, and 24-week time points]

      PROMIS® Sleep Disturbance-4a (A 5-point (5= Very poor to 1= Very good) rating scale is used in each of the 4 items; higher values reflect higher levels of sleep disturbances

    4. Pain Catastrophizing: Pain Catastrophizing Scale [Change from Baseline pain catastrophizing at 6, 12, and 24-week time points]

      Pain Catastrophizing Scale - short form(SF)-4a (A 4-point (0= Not at all to 4= All the time) rating scale is used in each of the 4 items; higher scores reflect greater pain catastrophizing

    5. Kinesiophobia [Change from Baseline kinesiophobia at 6, 12, and 24-week time points]

      Tampa Scale of Kinesiophobia (A 4-point (1= Strongly disagree to 4= Strongly agree) rating scale is used in each of the 11 items; higher values reflect higher levels of kinesiophobia

    6. Patient Perception of Change [12 weeks]

      Score on single item Patient Global Impression of Change Rating (range: 1 (No change) to 7 (a great deal better))

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    • age > 18 years

    • current non-specific cLBP that has persisted at least 3 months, and has resulted in pain on at least half the day in the past 6 months

    • proficient in English

    • average pain severity and interference ratings >3/10 on a 0-10 numeric rating scale

    • if taking pain medication(s), dosage must be stabilized for a minimum of 3 months

    • patients agree not to seek additional therapies for the duration of this study beyond those already included in their current treatment regimen or new treatments prescribed by their physician

    • naïve to DMT.

    • those who have adequate computer literacy (e.g., know how to use a computer to perform basic tasks such as open/send emails, use internet, fill-out online surveys) and access to the virtual delivery format (i.e., internet service and a personal computer device such as laptop, desktop, tablet PC).

    Exclusion Criteria:
    • pregnancy

    • severe and/or progressive medical, neurological, substance dependence within the last 6 months or severe mental illness (i.e., psychosis, mania) that would prevent active participation

    • cognitive impairment that prohibits informed consent

    • back surgery in the last 6 months

    • low back pain attributable to a recognizable, known specific pathology (e.g. infection, tumor, osteoporosis, fracture, structural deformity, inflammatory disorder, radicular syndrome, or cauda equina syndrome

    • wheelchair-bound or unable to move without assistance

    • involvement in impending litigation or judgment for disability or worker's compensation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Drexel Universitsy Philadelphia Pennsylvania United States 19102

    Sponsors and Collaborators

    • Drexel University
    • National Center for Complementary and Integrative Health (NCCIH)
    • Stony Brook University

    Investigators

    • Principal Investigator: Minjung Shim, PhD, Drexel University
    • Principal Investigator: Adam Gonzalez, PhD, Stony Brook University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Drexel University
    ClinicalTrials.gov Identifier:
    NCT03986489
    Other Study ID Numbers:
    • 1810006694
    • 7R34AT009555-02
    First Posted:
    Jun 14, 2019
    Last Update Posted:
    Apr 15, 2021
    Last Verified:
    Dec 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Drexel University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 15, 2021